APICMO Experienced PHD Team Focuses on Research and Development

APICMO Experienced PHD Team Focuses on Research and Development

Posted: Updated:

Specializing in key intermediates for new research and development in the medical industry, APICMO.com is proud to highlight the work of their professional PHD team

Yangpu District, Shanghai,China – August 30, 2018 /MarketersMedia/

APICMO, is a leading pharmaceutical company that takes pride in its PHD team experience in dealing with Merck, Lilly, and several other pharmaceutical companies. The company has a focus on research and development of cancer/tumor-targeted drug intermediates (API). Along with that, they are known to have mass production for CMO and CDMO orders.

The specialization of the company is in key intermediates related to new research and development in the field of oncology. It provides system development, mass production, synthetic customization, and several other services for a number of drug research and development institutions as well as pharmaceutical companies.

Among the products that APICMO offers include chemical and biologically derived pharmaceutical intermediates, fines, and APIs. The advantage of the company regarding drug research and development is in the advance of quality control, chemicals, marketing, project management, and cGMP manufacturing. All of which improves the company’s reach to other companies.

The pharmaceutical company can deliver the highest quality cancer key API thanks to its strong R&D team comprised of experienced scientists lead by Dr. Zeng Zhaosen. Furthermore, a large-scale production plant and business development management team supports the company. Besides, its APICMO team management has exceptional members.

The team management of APICMO includes members mostly from developed countries, including Japan, the United States, and Europe. They are cdmo and CMO professionals with more than enough knowledge and experience in this field. Moreover, APIMO has over ten years of industry experience dealing with multinational pharmaceutical companies.

“With more than a decade of market accumulation, clients of APICMO can rest assured that the company has a strong and broad base of cooperation in the industry of pharmaceutical intermediates,” stated company spokesperson Dr. Zeng. “The company’s vast array of products and services, as well as loyal clients, is more than enough evidence. Among the products that the company offer includes Heterocycles, Pyrimidines, Pyridines, Azetidines, Chiral compounds and other compounds.”

Additional information about the services provided by APICMO can be found by visiting the company’s website.

ABOUT APICMO

APICMO is a pharmaceutical company specializing in key intermediates for new research and development of oncology, providing system development, synthetic customization, mass production and other services for drug research and development institutions and

APICMO has a strong R&D team and experienced scientists. It has a large-scale production plant and business development management team. The APICMO team management members are mostly from developed countries such as the United States, Europe, and Japan. More than 10 years of industry experience in multinational pharmaceutical companies. After more than ten years of market accumulation, apicmo has a broad base of cooperation in the pharmaceutical intermediates industry.

Contact Info:
Name: DR.zeng
Email: info@apicmo.com
Organization: apicmo Biochemical Technology Co.,ltd
Address: Building D, 2 floor, No. 128, Xiangyin Road, Yangpu District, 200433, Shanghai, China
Phone: +8617620456565

Source URL: https://marketersmedia.com/apicmo-experienced-phd-team-focuses-on-research-and-development/400450

For more information, please visit https://www.apicmo.com

Source: MarketersMedia

Release ID: 400450

Information contained on this page is provided by an independent third-party content provider. Frankly and this Station make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com

Powered by Frankly